Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | +9,900.00% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
Sales 2021 | 28.9M 39.5M | Sales 2022 | 36.94M 50.49M | Capitalization | 5.79M 7.92M |
---|---|---|---|---|---|
Net income 2021 | -49M -66.98M | Net income 2022 | -57M -77.91M | EV / Sales 2021 | -0.2 x |
Net cash position 2021 | 39.64M 54.19M | Net cash position 2022 | 7.19M 9.83M | EV / Sales 2022 | -0.04 x |
P/E ratio 2021 |
-0.53
x | P/E ratio 2022 |
-0.09
x | Employees | 39 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.05% |
6 months | -99.98% |
Managers | Title | Age | Since |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 23-07-06 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 23-06-29 |
Steven Gelone
BRD | Director/Board Member | 56 | 17-06-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 17-06-22 |
Director/Board Member | 69 | 18-07-23 | |
Stephen Webster
BRD | Director/Board Member | 63 | 16-07-31 |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 323 | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- NBRVF Stock